Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19868510 | 0.83 | KMT2A (0.50) | KMT2AMAOBNPC1RAB9AALDH1A1 | |
| SCHEMBL707684 | 0.74 | NPC1 (0.66) | KMT2ANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL7807992 | 0.74 | KMT2A (0.54) | KMT2AMAOBNPC1RAB9AALDH1A1 | |
| SCHEMBL8917379 | 0.74 | KMT2A (0.86) | KMT2AMAOBNPC1RAB9AALDH1A1 | |
| SCHEMBL2333074 | 0.72 | ALOX15 (0.31) | — | |
| SCHEMBL2514710 | 0.72 | ALOX15 (0.31) | — | |
| SCHEMBL6598063 | 0.71 | NPC1 (0.41) | KMT2ANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL19865965 | 0.70 | KMT2A (0.50) | KMT2AMAOBNPC1RAB9AALDH1A1 | |
| Anthraquinone SCHEMBL27995581 | 0.69 | MEN1 (0.75) | KMT2AMAOBNPC1RAB9AALDH1A1 | |
| SCHEMBL19866022 | 0.67 | MAPT (0.53) | KMT2AMAOBNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306063-B2 | Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2022-04-19 | — | — | US | disclosed |
| EP-3497083-B1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2022-01-19 | — | — | EP | disclosed |
| EP-3497083-B1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2022-01-19 | — | — | EP | disclosed |
| EP-3497083-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169136-A1 | Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-06-06 | — | — | US | disclosed |
| US-20190169136-A1 | Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-06-06 | — | — | US | disclosed |
| WO-2018029137-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018029137-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-02-15 | — | — | WO | disclosed |
| EP-3281940-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (FR) | 2018-02-14 | — | — | EP | disclosed |
| EP-3281940-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (FR) | 2018-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306063-B2 | Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease | NEDD8, USP8, USP18 | KMT2A 1362/4885MAOB 2106/4885NPC1 575/4885 |
| US-20190169136-A1 | Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease | NEDD8, USP8, USP18 | KMT2A 1362/4885MAOB 2106/4885NPC1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.